🇺🇸 FDA
Patent

US 7612107

Treatment and inhibition of disease conditions using flexible heteroarotinoids

granted A61KA61K31/38A61K31/382

Quick answer

US patent 7612107 (Treatment and inhibition of disease conditions using flexible heteroarotinoids) held by The Board of Regents of the University of Oklahoma expires Mon Oct 29 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Oklahoma
Grant date
Tue Nov 03 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 29 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K31/38, A61K31/382, A61P, A61P1/16